2014 CME Symposia - Lunch Symposium A
Register for the CMHC today to sign up for these value-added CME/CE activities-at no additional cost!
Pre-registration for symposia will open at the end of August for CMHC registrants to make selections. There are no additional fees to attend. Symposia include meals or refreshments and seating is limited and on a first-come, first-serve basis.
CME Lunch Symposium A
Friday · 12:30 - 2:00pm
Triglyceride and Mixed Dyslipidemia Management: The Changing Landscape of CV Risk Reduction
Supported by an educational grant from AstraZeneca
Triglycerides are an increasingly important consideration when assessing cardiovascular risk. This symposium will address the prevalence of untreated hypertriglyceridemia and the importance of managing triglycerides to reduce cardiovascular risk. Recognized experts will discuss current guideline recommendations for hypertriglyceridemia and present data on new and emerging treatment options with a focus on comparing and contrasting the clinical data on prescription omega-3 fatty acids and novel combination therapies.
- Implement strategies to incorporate current guideline recommendations concerning LDL-C lowering, triglyceride and non-HDL-C management to clinical practice.
- Assess elevated triglyceride levels as a risk factor for cardiovascular disease.
- Identify patients who would benefit from a lipid management strategy that targets mixed dyslipidemias to reduce cardiovascular risk.
- Evaluate the safety, efficacy, tolerability, and cardiovascular outcomes data on available therapeutic strategies for lowering triglycerides.
- Discuss the overall observational and clinical trial evidence for CV event reduction with omega-3 fatty Acids.
- Discuss clinical trial data on available and emerging prescription omega-3 fatty acids, including data on their bioavailability and pharmacokinetic profiles.
Preliminary Agenda & Faculty
|12:30 - 12:35pm
||Chairperson: Christie M. Ballantyne, MD
|12:35 - 12:55pm
||Where Do We Stand with the Lipid Guidelines: Are LDL-C and Triglycerides Still Important?
|| Presenter: Michael Miller, MD
|12:55 - 1:15pm
||Managing CV Risk in Patients with High TG and Mixed Dyslipidemia: Recommendations and Best Practices
|| Presenter: Terry A. Jacobson, MD
|1:15 - 1:35pm
||What Is the Epidemiological and Clinical Trial Evidence for CVD Event Reduction with Omega-3 FAs and What Are the Mechanisms?
||Presenter: Dariush Mozaffarian, MD, DrPH
|1:35 - 2:00pm
||Optimizing the Management of Patients with High TG and Mixed Dyslipidemia
Interactive, Case-Based Scenarios, Panel Discussion and Debate along with Audience Q&A
|Moderator: Christie M. Ballantyne, MD
Discussants: Terry A. Jacobson, MD; Michael Miller, MD; Dariush Mozaffarian, MD, DrPH
Christie M. Ballantyne, MD
Professor of Medicine
Chief, Section of Cardiovascular Research
Chief, Section of Cardiology
Department of Medicine, Baylor College of Medicine
Director, Center for Cardiovascular Disease Prevention
Baylor College of Medicine
Methodist DeBakey Heart Center
Terry A. Jacobson, MD
- President, National Lipid Association
- Professor of Medicine, Emory University Director
- Office of Health Promotion & Disease Prevention
- Co-Director, Lipid & CV Risk Reduction Program
- Grady Health Systems
- Atlanta, GA
Michael Miller, MD
Professor of Medicine, Epidemiology & Public Health
University of Maryland School of Medicine
Director, Center for Preventive Cardiology
University of Maryland Medical Center
Dariush Mozaffarian, MD, DrPH
- Friedman School of Nutrition Science & Policy
- Tufts University
View Complete Accreditation Details and Program Overview: CMHC Accreditation